Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.
Nishie K, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, Omachi N, Asami K, Okishio K, Atagi S, Okuma T, Kubo A, Maruyama Y, Kudoh S, Takada M. Nishie K, et al. Among authors: asami k. J Thorac Oncol. 2012 Nov;7(11):1722-7. doi: 10.1097/JTO.0b013e31826913f7. J Thorac Oncol. 2012. PMID: 23059777 Free article.
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A. Kawaguchi T, et al. Among authors: asami k. J Clin Oncol. 2014 Jun 20;32(18):1902-8. doi: 10.1200/JCO.2013.52.4694. Epub 2014 May 19. J Clin Oncol. 2014. PMID: 24841974 Clinical Trial.
A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).
Asami K, Ando M, Nishimura T, Yokoi T, Tamura A, Minato K, Mori M, Ogushi F, Yamamoto A, Yoshioka H, Kawahara M, Atagi S. Asami K, et al. Thorac Cancer. 2022 Jun;13(12):1827-1836. doi: 10.1111/1759-7714.14465. Epub 2022 May 13. Thorac Cancer. 2022. PMID: 35562327 Free PMC article. Clinical Trial.
Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer.
Tamiya A, Tamiya M, Shiroyama T, Kanazu M, Hirooka A, Tsuji T, Morishita N, Asami K, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Hirashima T, Atagi S, Kawase I. Tamiya A, et al. Among authors: asami k. Ann Oncol. 2013 Apr;24(4):980-5. doi: 10.1093/annonc/mds544. Epub 2012 Nov 7. Ann Oncol. 2013. PMID: 23136232 Free article.
271 results